Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.

@article{Johnston2008PhaseIS,
  title={Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.},
  author={Stephen R. D. Johnston and Maureen Trudeau and Bella Kaufman and Hamouda Boussen and Kimberley Blackwell and Patricia Lorusso and Donald P Lombardi and Slim Ben Ahmed and Dennis L. Citrin and Michelle L Desilvio and Jennifer L Harris and Ron E Westlund and Vanessa Salazar and Tal Z. Zaks and Neil L. Spector},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 7},
  pages={1066-72}
}
PURPOSE Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. Lapatinib, an oral reversible inhibitor of epidermal growth factor receptor (EGFR) and human EGFR 2 (HER-2), demonstrated clinical activity in four of five IBC patients in phase I trials. We conducted a phase II trial to confirm the sensitivity of IBC to lapatinib, to determine whether response is HER-2 or EGFR dependent, and to elucidate a molecular signature predictive of lapatinib sensitivity… CONTINUE READING
89 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 89 extracted citations

Similar Papers

Loading similar papers…